Acute Myocardial Infarction Clinical Cohort

Summary

This prospective, multicenter, observational cohort study aims to establish a comprehensive clinical database and high-quality biobank for patients with Acute Myocardial Infarction (AMI) in China. The study plans to enroll 2,000 AMI patients across four major medical centers to collect standardized clinical data, multi-modality imaging, and biological samples.

A key focus of this study is the deep phenotyping of high-risk subgroups, including patients with vulnerable plaques, Myocardial Infarction with Non-obstructive Coronary Arteries (MINOCA), and borderline coronary lesions. By integrating advanced multi-omics sequencing (Whole Genome Sequencing, RNA-seq, single-cell RNA sequencing, and Olink proteomics) with cutting-edge AI-driven imaging radiomics (CCTA, OCT, IVUS, and novel intracoronary fluorescence imaging), the study seeks to elucidate the molecular mechanisms of AMI. The ultimate goal is to discover novel biomarkers for early warning, develop precise risk prediction models for Major Adverse Cardiovascular Events (MACE), and facilitate the development of personalized diagnostic and therapeutic strategies for AMI patients.

Conditions

• Acute Myocardial Infarction

Interventions

DIAGNOSTIC_TEST

Deep multi-omics analysis

Comprehensive molecular profiling of peripheral blood samples using a multi-omics approach. This includes Whole Genome Sequencing (WGS) to identify genetic variants, bulk RNA sequencing (RNA-seq) for transcriptomic profiling, single-cell RNA sequencing (scRNA-seq) to analyze immune cell heterogeneity in high-risk patients, and Olink multiplex assays for high-throughput proteomics (\>1,000 proteins). This analysis aims to identify novel circulating biomarkers and elucidate the molecular mechanisms of Acute Myocardial Infarction (AMI).

DIAGNOSTIC_TEST

Advanced AI-Driven Cardiovascular Imaging

Detailed morphological and functional assessment of coronary arteries using advanced imaging modalities combined with artificial intelligence (AI) and radiomics. Assessments include Coronary Computed Tomography Angiography (CCTA) plaque radiomics, Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS), Quantitative Flow Ratio (QFR) for hemodynamics, and novel Intracoronary Fluorescence Imaging. These tools are utilized to quantitatively evaluate plaque vulnerability, predict rupture risk, and develop AI-based prognostic models for AMI patients.

Sponsors & Collaborators

• Shanghai 10th People's Hospital

  collaborator OTHER

• Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

  collaborator OTHER

• RenJi Hospital

  collaborator OTHER

• Shanghai Zhongshan Hospital

  lead OTHER

Eligibility

Min Age

14 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-04-01

Primary Completion

2026-12-31

Completion

2028-12-31

Countries

• China

Study Locations